As the gene therapy field strives to strike the balance between clinical efficacy and product safety in the context of mounting regulatory scrutiny, the 3rd Annual Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs, including Refeyn, to develop robust analytical tools to guarantee the consistency, quality and safety of gene therapy products.

Focused specifically on addressing the unique analytical challenges posed by AAV, lentiviral and non-viral gene therapy products, this technical scientific conference will unite the ‘boots on the ground’ scientists from the leading companies grappling with these challenges first-hand.

With in-depth content on developing clinically relevant potency assays, utiliding next generation sequencing and digital PCR to interrogate your product and uncovering next generation technologies to assess empty vs full capsids, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development.